N-Acetyl Cysteine (NAC)

N-acetyl cysteine (NAC) occupies an unusual position in the supplement world: it is an FDA-approved drug (as Mucomyst for mucolytic therapy and as an IV antidote for acetaminophen poisoning) that was also sold as a dietary supplement for decades. In 2020, the FDA briefly challenged its supplement status, arguing it was first approved as a drug in 1963 and therefore could not be sold as a supplement under DSHEA. After significant industry pushback and a public comment period, the FDA issued a final guidance in 2022 effectively allowing NAC to remain on the market as a supplement. This regulatory history is worth understanding because it underscores that NAC has more pharmaceutical-grade evidence behind it than most supplements.

The strongest evidence for supplemental NAC is in chronic obstructive pulmonary disease (COPD). A Cochrane systematic review by Poole et al. (2019, PMID: 31107966) analyzed 39 trials with 7,436 participants and found that oral NAC (typically 600mg twice daily) significantly reduced the frequency of COPD exacerbations compared to placebo. The effect was modest but consistent. An earlier landmark RCT, the BRONCUS trial (Decramer et al. 2005, PMID: 16109458, n=523), found no significant effect on FEV1 decline over 3 years, but did show a reduction in exacerbation frequency in patients not already on inhaled corticosteroids. The PANTHEON trial (Zheng et al. 2014, PMID: 24477426, n=1,006) found that 600mg NAC twice daily reduced acute exacerbations by 22% over one year in Chinese COPD patients. Taken together, the respiratory evidence is solid for exacerbation reduction, though NAC does not slow lung function decline.

For immune function and influenza, the most frequently cited study is De Flora et al. (1997, PMID: 9230243), a double-blind RCT of 262 elderly subjects given 600mg NAC twice daily for 6 months during flu season. NAC did not reduce infection rates (seroconversion was similar), but significantly reduced the frequency and severity of symptomatic influenza episodes. Only 25% of NAC-treated subjects who seroconverted developed symptoms, versus 79% in the placebo group. This is a striking result, but it remains a single trial from nearly 30 years ago and has not been adequately replicated.

In psychiatry, NAC has accumulated an interesting evidence base. A meta-analysis by Deepmala et al. (2015, PMID: 25458990) reviewed NAC across multiple psychiatric conditions and found the most consistent benefits for obsessive-compulsive disorder (OCD) and trichotillomania (hair-pulling disorder), typically at 1,200-2,400mg/day as an adjunct to standard treatment. Grant et al. (2009, PMID: 19581567) published an influential RCT showing NAC at 1,200mg/day significantly reduced trichotillomania symptoms over 12 weeks compared to placebo. However, results for depression and bipolar disorder have been inconsistent, with the large EXACT trial (Berk et al. 2019, n=252) finding no benefit for bipolar depression at 2,000mg/day.

NAC has also been studied for polycystic ovary syndrome (PCOS). A meta-analysis by Thakker et al. (2015, PMID: 25460557) found that NAC improved ovulation rates in women with PCOS undergoing clomiphene citrate treatment, with results comparable to metformin in some trials. The doses used were typically 1,200-1,800mg/day. This is a moderate evidence base - promising but not yet definitive.

The mechanism underlying most of these effects is NAC's role as a precursor to glutathione, the body's primary intracellular antioxidant. NAC provides cysteine, the rate-limiting amino acid for glutathione synthesis. This mechanism is well-established biochemically, but "boosts glutathione" alone is not a clinical endpoint. The practical question is whether raising glutathione levels through supplementation produces measurable health benefits in specific conditions, and the answer varies considerably depending on the condition in question.